Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors

Molecular Cancer Therapeutics

Volumn 1, Issue 12, 2002, Pages 1129-1137

  Mulryan, Kate ^a   Ryan, Matthew G ^b   Myers, Kevin A ^b   Shaw, David ^a   Wang, Who ^a   Kingsman, Susan M ^b   Stern, Peter L ^a   Carroll, Miles W ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b OXFORD BIOMEDICA UK LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; MEMBRANE PROTEIN; TROPHOBLASTIC GLYCOPROTEIN 5T4, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; CELL SEPARATION; CHEMISTRY; CYTOLOGY; EXPERIMENTAL MELANOMA; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; MOLECULAR CLONING; MOUSE; NEOPLASM; POLYACRYLAMIDE GEL ELECTROPHORESIS; SPLEEN; TIME; VACCINIA VIRUS; WESTERN BLOTTING;

ANIMALS; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CANCER VACCINES; CELL SEPARATION; CLONING, MOLECULAR; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS; SPLEEN; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; VACCINIA VIRUS;

EID: 1842848097     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Stern, P., Beverley, P., and Carroll, M. Cancer Vaccines and Immunotherapy, p. 286. Cambridge, UK: Cambridge University Press, 2000.
2. Hole, N., and Stern, P. L. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br. J. Cancer, 57: 239-246, 1988. (Pubitemid 18096328)
3. Southall, P. J., Boxer, G. M., Bagshawe, K. D., Hole, N., Bromley, M., and Stern, P. L. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br. J. Cancer, 61: 89-95, 1990.
4. Hole, N., and Stern, P. L. Isolation and characterization of 5T4, a tumor-associated antigen. Int. J. Cancer, 45: 179-184, 1990. (Pubitemid 20032118)
5. Jones, H., Roberts, G., Hole, N., McDicken, I. W., and Stern, P. Investigation of expression of 5T4 antigen in cervical cancer. Br. J. Cancer, 61: 96-100, 1990. (Pubitemid 20043553)
6. Starzynska, T., Marsh, P. J., Schofield, P. F., Roberts, S. A., Myers, K. A., and Stern, P. L. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br. J. Cancer, 69: 899-902, 1994. (Pubitemid 24140671)
7. Starzynska, T., Wiechowska Kozlowska, A., Marlicz, K., Bromley, M., Roberts, S. A., Lawniczak, M., Kolodziej, B., Zyluk, A., and Stern, P. L. 5T4 oncofetal antigen in gastric carcinoma and its clinical significance. Eur. J. Gastroenterol. Hepatol., 10: 479-484, 1998. (Pubitemid 28306540)
8. Wrigley, E., McGown, A. T., Rennison, J., Swindell, R., Crowther, D., Starzynska, T., and Stern, P. L. 5T4 oncofetal antigen expression in ovarian carcinoma. Int. J. Gynecol. Cancer, 5: 269-274, 1995.
9. Starzynska, T., Rahi, V., and Stern, P. L. The expression of 5T4 antigen in colorectal and gastric carcinoma. Br. J. Cancer, 66: 867-869, 1992.
10. Shaw, D. M., Woods, A. M., Myers, K., Westwater, C., Rahi-Saund, V., Davies, M. J., Renouf, D. V., Hounsell, E. F., and Stern, P. L. The glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen: a target for antibody directed therapy. Biochem. J., 363: 137-145, 2002. (Pubitemid 34280620)
11. Myers, K. A., Rahi Saund, V., Davison, M. D., Young, J. A., Cheater, A. J., and Stern, P. L. Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein. An antigen associated with metastasis contains leucine-rich repeats. J. Biol. Chem., 269: 9319-9324, 1994.
12. Carsberg, C. J., Myers, K. A., and Stern, P. L. Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int. J. Cancer, 68: 84-92, 1996. (Pubitemid 26354583)
13. King, K. W., Sheppard, F. C., Westwater, C., Stern, P. L., and Myers, K. A. Organisation of the mouse and human 5T4 oncofoetal leucine-rich glycoprotein genes and expression in foetal and adult murine tissues. Biochim. Biophys. Acta, 1445: 257-270, 1999. (Pubitemid 29298033)
14. Woods, A. M., Wang, W. W., Shaw, D. M., Ward, C. M., Carroll, M. W., Thomas, B., and Stern, P. L. Characterization of murine 5T4 oncofetal antigen- a target for immunotherapy in cancer. Biochem. J., 366: 353-365.
15. Flexner, C., and Moss, B. New generation vaccines: vaccinia virus as a live vector for the expression of immunogens. In: M. M. M. Levine (ed.), Vaccines, Ed. 2., pp. 297-314. New York: Marcel Dekker Inc., 1997.
16. Overwijk, W. W., Lee, D. S., Surman, D. R., Irvine, K. R., Touloukian, C. E., Chan, C. C., Carroll, M. W., Moss, B., Rosenberg, S. A., and Restifo, N. P. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc. Natl. Acad. Sci. USA, 96: 2982-2987, 1999.
17. Carroll, M. W., and Restifo, N. P. Cancer Vaccines and Immunotherapy, Chapter 3. Poxviruses as Vectors for Cancer Immunotherapy, pp. 47-61. Cambridge, UK: Cambridge University Press, 2000.
18. Mahnel, H., and Mayr, A. Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA. Berl. Munch. Tierarztl. Wochenschr., 107: 253-256, 1994.
19. Meyer, H., Sutter, G., and Mayr, A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol., 72: 1031-1038, 1991.
20. Sutter, G., and Moss, B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA, 89: 10847-10851, 1992.
21. Carroll, M. N. and Moss, B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nontumor mammalian cell line. Virology, 238: 198-211, 1997. (Pubitemid 28218138)
22. Carroll, M. W., Overwijk, W. W., Chamberlain, R. S., Rosenberg, S. A., Moss, B., and Restifo, N. P. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine, 15: 387-394, 1997. (Pubitemid 27156156)
23. Brattain, M. G., Strobel Stevens, J., Fine, D., Webb, M., and Sarrif, A. M. Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res., 40: 2142-2146, 1980. (Pubitemid 10082214)
24. Winkelhake, J. L., and Nicolson, G. L. Determination of adhesive properties of variant metastatic melanoma cells to BALB/3T3 cells and their virus-transformed derivatives by a monolayer attachment assay. J. Natl. Cancer Inst., 56: 285-291, 1976.
25. Rees, S., Coote, J., Stables, J., Goodson, S., Harris, S., and Lee, M. G. Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques, 20: 102-110, 1996. (Pubitemid 26025524)
26. Shaw, D. M., Embleton, M. J., Westwater, C., Ryan, M. G., Myers, K. A., Kingsman, S. M., Carroll, M. W., and Stern, P. L. Isolation of a high affinity scFV from a monoclonal antibody recognising the oncofetal antigen 5T4. Biochim. Biophys. Acta, 1524: 238-246, 2000.
27. Durbin, A. P., Wyatt, L. S., Siew, J., Moss, B., and Murphy, B. R. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys. Vaccine, 16: 1324-1330, 1998. (Pubitemid 28308414)
28. Earl, P., Wyatt, L. S., Cooper, N., Moss, B., and Carroll, M. W. 1998 Preparations of Cell Cultures and Vaccinia Virus Stocks. Current Protocols in Molecular Biology Suppl. 43 13: Unit 16.16.1-16.16, 1998.
29. Kalpan, E., and Meier, P. Non parametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
30. Mann, H. B., and Whitney, D. R. On a test of whether one of two random variables is stochastically larger than the other. Ann. Math. Stat., 18: 50-60, 1947.
31. Overwijk, W., Tsung, A., Irvine, K., Parkhurst, M., Goletz, T., Tsung, K., Carroll, M., Liu, C., Moss, B., Rosenberg, S., and N. P. R. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med., 188: 277-286, 1998.
32. Kerr, P. J., J. R., Robinson, A. J., Swan, J., Silvers, L., French, N., Clarke, H., Hall, D. F., and Holland, M. K. Infertility in female rabbits (Oryctolagus cuniculus) alloimmunized with the rabbit zona pellucida protein ZPB either as a purified recombinant protein or expressed by recombinant myxoma virus. Biol. Reprod., 61: 606-613, 1999. (Pubitemid 29402618)
33. Jackson, R. J., M. D., Hinds, L. A., and Ramshaw, I. A. Infertility in mice induced by a recombinant ectromelia virus expressing mouse zona pellucida glycoprotein 3. Biol. Reprod., 58: 152-159, 1998. (Pubitemid 28023745)
34. He, Z., P., W. A., Kowalczyk, D. W., Cheng, J., Xiang, Z. Q., Giles-Davis, W., and Ertl, H. C. J. Viral Recombinant Vaccines to the E6 and E7 Antigens of HPV-16. Virology, 270: 146-161, 2000.
35. Soares, M. M., Mehta, V., and Finn, O. J. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J. Immunol., 166: 6555-6563, 2001. (Pubitemid 32467194)
36. Bright, R., Shearer, M., and Kennedy, R. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. An antibody-based mechanism for tumor immunity. J. Immunol., 153: 2064-2071, 1994.
37. Mendiratta, S. K., Thai, G., Eslahi, N. K., Thull, N. M., Matar, M., Bronte, V., and Pericle, F. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. Cancer Res., 61: 859-863, 2001. (Pubitemid 32174392)
38. Syrengelas, A. D., Levy, R. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J. Immunol., 162: 1790-1795, 1999.
39. Kwak, L. W., Y. H., Pennington, R. W., and Weeks, S. D. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA, 93: 10972-7, 1996. (Pubitemid 26333102)
40. Ossendorp, F., M. E., Camps, M., Filius, R., and Melief, C. J. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med., 187: 693-702, 1998. (Pubitemid 28115185)
41. Tsuji, K., O. Y., Takahashi, T., Arata, J., and Nakayama, E. Requirement of CD4 T cells for skin graft rejection against thymus leukemia (TL) antigen and multiple epitopes on the TL molecule recognized by CD4 T cells. J. Immunol., 159: 159-166, 1997. (Pubitemid 127493697)
42. Ramirez, J. C., Gherardi, M. M., and Esteban, M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J. Virol., 74: 923-933, 2000. (Pubitemid 30036229)
43. Snapper, C. M., McIntyre, T. M., Mandler, R., Pecanha, L. M., Finkelman, F. D., Lees, A., and Mond, J. J. Induction of IgG3 secretion by interferon γ: a model for T cell-independent class switching in response to T cell-independent type 2 antigens. J. Exp. Med. 175: 1367-1371, 1992.
44. Mascher, B., Schlenke, P., and Seyfarth, M. Expression and kinetics of cytokines determined by intracellular staining using flow cytometry. J. Immunol. Methods., 223: 115-121, 1999. (Pubitemid 29096243)
45. Becker, C., Pohla, H., Frankenberger, B., Schuler, T., Assenmacher, M., Schendel, D. J., and Blankenstein, T. Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay. Nat. Med., 7: 1159-1162, 2001. (Pubitemid 33010027)
46. Carroll, M. W., O. W., Surman, D. R., Tsung, K., Moss, B., and Restifo, N. P. Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen. J. Natl. Cancer Inst., 90: 1881-1887, 1998. (Pubitemid 29014221)
47. van der Burg, S. H., K. K., O'Neill, T., Brandt, R. M., Melief, C. J., Hickling, J. K., and Offringa, R. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine, 19: 3652-3660, 2001.
48. Tartaglia, J., B. M., Berinstein, N., Barber, B., Klein, M., and Moingeon, P. Therapeutic vaccines against melanoma and colorectal cancer. Vaccine, 19: 2571-2575, 2001.
49. Diehl L, D. B. A., van der Voort, E. I., Melief, C. J., Offringa, R., and Toes, R. E. The role of CD40 in peripheral T cell tolerance and immunity. J. Mol. Med., 78: 363-371, 2000.
50. Sutmuller, R. P., v. D. L., van Elsas, A., Schumacher, T. N., Wildenberg, M. E., Allison, J. P., Toes, R. E., Offringa, R., and Melief, C. J. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med., 194: 823-832, 2001. (Pubitemid 32983017)
51. Adams, M., Jasani, B., Colaco, C. A. L. S., and Mason, M. D. Cancer Vaccines and Immunotherapy, Chapter 13 Dendritic Cell Approaches to Immunotherapy, pp. 237-255. Cambridge, UK: Cambridge University Press, 2000.
52. Garrido, F. R-C., F, Cabrera, T., Pérez-Villar, J. J., López-Botet, M., Duggan-Keen, M., and Stern, P. L. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today, 18: 89-95, 1997.
53. Forsberg, G. O. L., Brodin, T., Bjork, P., Lando, P. A., Shaw, D., Stern, P. L., and Dohlsten, M. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br. J. Cancer, 85: 129-136, 2001. (Pubitemid 32695728)
54. Myers, K. A., Ryan, M. G., Shaw, D. M., Embleton, M. J., Stern, P. L., Kingsman, S. M., and Carroll, M. W. Tumour cell targeting of immune effector molecules using tumour associated antigen specific scFv fusion proteins. Cancer Gene Ther., in press, 2002.